PHEN and Johns Hopkins Partnered to Host Highly Effective Clinical Trials Learning Session

On March 2, 2023, PHEN partnered with the Johns Hopkins Sidney Kimmel Cancer Center to host a clinical trials learning session aimed at increasing the understanding and participation of Black patients in prostate cancer clinical trials. The Learning Session, a virtual webinar, was introduced by PHEN President Thomas A. Farrington who explained that Black patients have not obtained the full benefits of clinical research because of a lack of participation in clinical trials. PHEN’s Director of Clinical Trials and Patient Education, Dr. Keith Crawford, and Johns Hopkins trial investigators Dr. Catherine H. Marshall and Dr. Samuel Denmeade presented specific trials for review. The trials included the PROMISE registry for genetic testing and BAT for bipolar androgen therapy. The recorded learning session will be available on The 35 patients in attendance participated in surveys before and after the learning session with the results highlighting the effectiveness of the session. For example, 95% of attendees answered that they are “very likely” to recommend PHEN clinical trials learning sessions to others. Other post-session survey results highlights: •	79% of patients better understand clinical trials, the enrollment steps, and their potential benefits better than before. •	100% of patients are more likely to seek appropriate clinical trials for themselves. •	89% of patients stated that the learning session improved their trust in clinical trials. About four out of five patients taking the survey have not participated in any prostate cancer clinical trial. Yet, after the learning session, all will now consider participating in relevant clinical trials. The post learning session survey results are available here.

PHEN,Inc. © 2024 All rights reserved